<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948138</url>
  </required_header>
  <id_info>
    <org_study_id>GLN-9-MIT</org_study_id>
    <nct_id>NCT04948138</nct_id>
  </id_info>
  <brief_title>Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome</brief_title>
  <official_title>Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome in Order to Prevent Neurological Damage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jesús González de la Aleja Tejera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario 12 de Octubre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assesses the efficacy of oral supplementation with glutamine&#xD;
      over three months on several amino acids and lactate concentration measured in cerebrospinal&#xD;
      fluid and cerebral lactate measured by magnetic resonance spectroscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome&#xD;
      is a genetically heterogeneous disorder. The most common mutation is in the mtDNA gene MT-TL1&#xD;
      encoding the mitochondrial tRNALeu (UUR). For understanding the development of seizures in&#xD;
      patients with mitochondrial disease, a study has recently emphasized the deficiency of&#xD;
      astrocytic glutamine synthetase, creating a disinhibited neuronal network for seizure&#xD;
      generation. The investigators propose to evaluate nine patients with mitochondrial DNA&#xD;
      mutation and MELAS. Patients will receive oral supplementation with 10-15 g/day of glutamine&#xD;
      (adjusted for weight and plasma concentrations). The primary outcome measures several amino&#xD;
      acids (including glutamine) and lactate concentration measured in cerebrospinal fluid and&#xD;
      cerebral lactate measured by magnetic resonance spectroscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Actual">October 6, 2021</completion_date>
  <primary_completion_date type="Actual">September 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Glutamine oral supplementation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amino Acids concentration in cerebrospinal fluid</measure>
    <time_frame>3 months</time_frame>
    <description>Amino Acids (including glutamine) concentration measured in cerebrospinal fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate concentration in cerebrospinal fluid</measure>
    <time_frame>3 months</time_frame>
    <description>Lactate concentration measured in cerebrospinal fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate measured by magnetic resonance spectroscopy.</measure>
    <time_frame>3 months</time_frame>
    <description>Cerebral Lactate measured by magnetic resonance spectroscopy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>MELAS Syndrome</condition>
  <arm_group>
    <arm_group_label>MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MELAS syndrome that will receive oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutamine oral supplementation</intervention_name>
    <description>Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).</description>
    <arm_group_label>MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The diagnosis of MELAS syndrome is based on medical history (lactic acidosis,&#xD;
             stroke-like episodes, and encephalomyopathy).&#xD;
&#xD;
          -  Subjects have to be clinically stable for more than six months after any stroke-like&#xD;
             episodes.&#xD;
&#xD;
          -  All subjects have to be genetically confirmed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects harboring a MELAS-related pathogenic mtDNA mutation, no fulfilling the&#xD;
             complete diagnostic criteria for the MELAS phenotype.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús González de la Aleja Tejera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario 12 de Octubre</investigator_affiliation>
    <investigator_full_name>Jesús González de la Aleja Tejera</investigator_full_name>
    <investigator_title>Jesús González de la Aleja Tejera, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>MELAS</keyword>
  <keyword>Glutamine</keyword>
  <keyword>Oral supplements</keyword>
  <keyword>Lactate</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MELAS Syndrome</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

